Positions

Overview

  • I am a Physician Scientist at the University of Alabama at Birmingham Comprehensive Cancer Center. I conduct clinical and translational research in breast cancer and I am the principal investigator for many clinical trials. My research in the lab focuses on translational (mRNA to protein) dysregulation and intends to address a critical, yet elusive, fundamental biologic question, i.e. in a competing pool of mRNAs, how breast cancer cells mis-prioritize the translation of certain mRNAs that allow for their proliferation and survival. With the support from ASCO Young Investigator Award and currently Susan G Komen Career Catalyst Award, I have adapted next-generation sequencing methods to visualize translational regulation at a global genomic scale. The knowledge gained from this work will advance our understanding of challenging clinical problems including tumor persistence, growth, and therapeutic resistance.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast CancerJournal of Clinical Oncology.  37:714-722. 2019
    2018 Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibitionOncology Reports.  39:2482-2498. 2018
    2017 Translational dysregulation in cancer: Molecular insights and potential clinical applications in biomarker developmentFrontiers in Oncology.  7. 2017
    2017 Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical applicationOncotarget.  8:16052-16074. 2017
    2016 IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cellsTumor Biology.  37:13247-13264. 2016
    2015 Small molecule inhibitors of IRES-mediated translationCancer Biology and Therapy.  16:1471-1485. 2015
    2015 Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Seminars in Oncology.  42:e67-e79. 2015
    2015 Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019Clinical Cancer Research.  21:2771-2779. 2015
    2015 TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancerClinical Cancer Research.  21:2722-2729. 2015
    2014 Management of metastatic breast cancer with second-generation antibody-drug conjugates: Focus on Glembatumumab vedotin (CDX-011, CR011-vcMMAE)Clinical immunotherapeutics.  28:253-263. 2014
    2013 Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: The MD Anderson experienceActa hepato-splenologica.  60:1611-1623. 2013
    2013 Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphomaCancer Biotherapy and Radiopharmaceuticals.  28:370-379. 2013
    2013 A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancerSeminars in Oncology.  40:135-144. 2013
    2012 Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase i clinical trials program at the MD Anderson Cancer CenterCancer.  118:1422-1428. 2012
    2012 By the pricking of my thumbs, something wicked this way comes*: Sporadic cancers versus eponymous hereditary cancer predisposition syndromesJournal of the National Comprehensive Cancer Network.  10:7-13. 2012
    2012 Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaTherapeutic Advances in Hematology.  3:209-225. 2012
    2011 Common cardiovascular medications in cancer therapeuticsPharmacology and Therapeutics.  130:177-190. 2011
    2011 A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogeneticsClinical Lymphoma, Myeloma and Leukemia.  11:521-524. 2011
    2011 How do i treat "Triple-Negative" diseaseCurrent Treatment Options in Oncology.  12:369-388. 2011
    2011 Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center ExperienceCancer.  117:77-85. 2011
    2011 The changing perspective of cardiology in cancer careExpert Review of Cardiovascular Therapy.  9:1-3. 2011
    2010 Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppressionVirology Journal.  7. 2010
    2010 Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatmentDrug Safety.  33:171-187. 2010
    2010 Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemiasClinical Cancer Research.  16:1149-1158. 2010
    2010 Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target?Oncologist.  15:130-141. 2010
    2009 Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: The MD anderson cancer center experienceJournal of Pediatric Hematology/Oncology.  31:803-811. 2009
    2009 Molecular basis of statin-associated myopathyAtherosclerosis.  202:18-28. 2009
    2009 Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experienceJournal of Clinical Endocrinology and Metabolism.  94:4423-4432. 2009
    2008 Coenzyme Q10 Depletion: Etiopathogenic or Predisposing Factor in Statin Associated Myopathy?American Journal of Cardiology.  101:1071. 2008
    2007 'Idiopathic' eosinophilia with an Occult T-cell clone: Prevalence and clinical courseLeukemia Research.  31:691-694. 2007
    2004 Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin graftsTechniques in Coloproctology.  8. 2004

    Chapter

    Year Title Altmetric
    2013 Brentuximab vedotin (SGN-35) for CD30-positive malignancies.  161-175. 2013
    2013 CDX-011 (Glembatumumab vedotin, CR011-vcMMAE).  211-220. 2013

    Research Overview

  • Breast Cancer
    Translational research
    Gene-specific translational dysregulation
  • Education And Training

  • Doctor of Medicine, Aristotle University of Thessaloniki 2000
  • University of Texas Health Science Center, Residency 2009
  • UAB Hospital, Postdoctoral Fellowship 2013
  • MD Anderson Cancer Center, Postdoctoral Fellowship 2010
  • Full Name

  • Christos Vaklavas